For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Takeda Suspends Shipment of All ASKA Pharma Products
March 28, 2011
- Astellas Settles Dispute over Tarceva Patents with Teva
March 28, 2011
- JAMS Cancels 2011 General Assembly
March 28, 2011
- Fuso's Replacement Fluid in Short Supply
March 28, 2011
- Sales by Member Companies Up 0.2% in 2010: JCROA
March 28, 2011
- Most Scientific Meetings Postponed or Cancelled
March 28, 2011
- Maintain Electric Power to Ensure Stable Drug Supply: FPMAJ
March 28, 2011
- Drugstore Sales Up 3.5% in FY2010: JACDS
March 28, 2011
- Change in Prescription Form Proposed by JSGM President
March 28, 2011
- Requests for Frequent Delivery Abating in Tohoku: Wholesalers
March 28, 2011
- R&I to Downgrade Terumo Following Announcement of Acquisition of CaridianBCT
March 21, 2011
- Korosho to Extend HPV Vaccination Period for Girls Currently in 1st Grade of Senior High School
March 21, 2011
- JACDS May Violate Antimonopoly Act by Calling on Members Not to Offer Point Cards
March 21, 2011
- MSD K.K. Submits NDA for Caspofungin
March 21, 2011
- Nichiyakubo to Call For Improvement of Drug Substance Import System
March 21, 2011
- Eli Lilly's Gemzar Receives Add'l Indication for Ovarian Cancer
March 21, 2011
- Astellas to Challenge New Field of Regenerative Medicine
March 21, 2011
- Herceptin Approved for Gastric Cancer as Add'l Indication
March 21, 2011
- Shionogi Terminates Development of S-2367 for Obesity Drug in the US, Europe
March 21, 2011
- Stiripentol Designated as Orphan Drug
March 21, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…